Last updated: July 27, 2026
ecutive summary
Gilead Sciences, Inc. v. SigmaPharm Laboratories, LLC (D.N.J., Case No. 1:15-cv-04898) is a patent-infringement dispute tied to Gilead’s HIV portfolio. The case name and docket number provided are sufficient to produce a high-level litigation summary and competitive takeaways, but not sufficient to compile a complete, citation-anchored analysis of asserted patents, claim construction, procedural posture, or outcome without pulling the docket/patent asserted list from court records.
What happened in Gilead Sciences v. SigmaPharm 1:15-cv-04898?
Key litigation elements identifiable from the case header
- Plaintiff: Gilead Sciences, Inc.
- Defendant: SigmaPharm Laboratories, LLC
- Court / case number: U.S. District Court (case caption reflects D.N.J.), 1:15-cv-04898
- Case type (by inference from title only): Patent litigation (commonly Hatch-Waxman related when parties are generic vs. innovator), but the specific mechanism (e.g., Paragraph IV under 21 U.S.C. § 355(j)(2)(A)(vii)/(B), declaratory judgment, or direct infringement) cannot be stated from the provided input alone.
What a business user should extract from the docket (without inventing specifics)
A litigation summary that supports licensing, clearance, or investment decisions must include:
- Asserted patents and owners
- Patents-in-suit’ expiration and terminal disclaimer posture
- ANDA / FDA filing link (if applicable)
- Claim construction orders and infringement theories
- Procedural milestones (initial complaint date, responsive filings, Markman, summary judgment, trial, judgment)
- Disposition (dismissal, settlement, consent judgment, or judgment after trial)
Those items require docket/paper access. The prompt does not provide them.
Which patents were asserted in Gilead v. SigmaPharm (1:15-cv-04898)?
What matters for freedom-to-operate (FTO)
For generic market entry planning, the asserted set determines:
- Whether the generic product is blocked by composition, formulation, or method-of-use claims
- Whether a design-around is feasible (process or polymorph vs. active ingredient vs. dosing regimen)
- The probability of an injunction or a carve-out settlement
- The amount of “patent thicket” risk around likely FDA exclusivity cliffs
What cannot be determined from the provided information
No patent list, patent numbers, or Orange Book mapping is included in the request. Without that, an accurate “how many patents” answer would be fabricated.
What was the procedural posture in 1:15-cv-04898 (complaint, Markman, summary judgment, trial)?
Milestones that drive deal timing
- Complaint filing date: controls notice timing and any applicable early case schedule
- Answer and counterclaims: can indicate invalidity defenses or non-infringement scope
- Claim construction (Markman): sets the infringement litigation framework
- Summary judgment: often resolves key issues before trial
- Final judgment or settlement: drives authorized generic timing and launch calendars
What cannot be stated
The dates and outcomes for each milestone are not included in the prompt.
What settlement terms or injunction risks applied in Gilead v. SigmaPharm?
What to look for in settlement/injunction outcomes
For Hatch-Waxman-style disputes, settlement records often include:
- Launch date triggers (designated “at-risk” dates)
- Carve-outs for non-infringing products or alternative strengths
- Stipulated injunction scope (which claims, which SKUs)
- Payment amounts (if any) and mutual covenants
- Future dispute provisions (e.g., reversion to litigation upon FDA amendments)
What cannot be concluded from the provided data
No settlement agreement details, consent judgment, or injunction order is included.
Is this case linked to an ANDA or Paragraph IV certification (Orange Book status)?
Business relevance
An ANDA/Paragraph IV mapping is the cleanest way to connect:
- the innovator’s listed patents on the FDA Orange Book
- the defendant’s Paragraph IV notice and litigation trigger
- the likely FDA approval pathway timing (and any 30-month stay)
What cannot be answered
No ANDA number, listed drug, or certification type is included in the prompt, so an Orange Book status analysis cannot be produced without court documents.
How does this litigation affect SigmaPharm’s generic launch risk for Gilead products?
Risk framework (what decision-makers use)
- Claim strength: composition/formulation vs. method-of-use vs. dosing regimen
- Infringement map: whether the product literally meets limitations or is plausibly non-infringing
- Validity challenges: obviousness, written description, enablement, prosecution history estoppel
- Remedy posture: injunction vs. damages-only outcome probability
- Design-around feasibility: salt form, prodrug choice, particle size, dosing schedule
What cannot be quantified here
Without asserted patents and factual product details, the probability of launch-blocking or “at-risk” entry cannot be calculated.
What is the competitive landscape for Gilead’s HIV portfolio vs. SigmaPharm in 2015–2016?
What a competitive patent landscape review typically covers
- Which other ANDA filers were challenging the same innovators’ Orange Book patents
- Whether those cases settled on similar launch timelines
- Whether multiple patents were asserted, producing settlement layers
What cannot be answered
The prompt gives only the case caption and docket number. No drug identity or parallel litigation list is provided.
Key takeaways
- The request contains insufficient case record data to produce a complete litigation summary with asserted patents, dates, claim construction, and outcome.
- A reliable, decision-grade analysis of infringement/validity posture, settlement or injunction exposure, and launch calendar impact requires the docket’s substantive filings and the patent-in-suit list, none of which are provided.
FAQs
- What is the docket number for Gilead Sciences v. SigmaPharm Laboratories?
1:15-cv-04898.
- Which court heard Gilead v. SigmaPharm in this caption?
The caption indicates the U.S. District Court for the District of New Jersey.
- Is this case a Paragraph IV Hatch-Waxman dispute?
The prompt does not state the FDA pathway or Paragraph IV certifications.
- What determines the generic launch timing after a Gilead vs. SigmaPharm patent case?
The patents-in-suit, injunction scope, and any settlement-triggered launch dates.
- How do claim construction rulings change infringement risk in Gilead-style HIV cases?
They define claim term scope that directly controls literal infringement vs. design-around.
References
- Gilead Sciences, Inc. v. SigmaPharm Laboratories, LLC, No. 1:15-cv-04898 (D.N.J.).
